Marvel Biosciences Lead Asset MB-204 Show 47% Reduction in Liver Fibrosis and Active Indications in Multiple Pre-Clinical Models of Nash

Calgary, Alberta--(Newsfile Corp. - November 23, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today announced that it has found its lead asset, MB-204 was active in two different pre-clinical models of non-alcoholic steatohepatitis ("NASH") using fibrosis and the non-alcoholic fatty liver...

Marvel Biosciences Announces New Program to Develop Novel Orally Dosed Non-Hallucinogenic Neuroplastic Promoting Compounds

Calgary, Alberta--(Newsfile Corp. - October 27, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that the Company has initiated a new program whose goal is to identify and develop novel, safe agents that promote neuroplasticity without the liabilities of abuse potential or...

Marvel Biosciences Provides Updates on the Status of Its MB-204 Manufacturing Efforts and Sets Out Future Milestones

Calgary, Alberta--(Newsfile Corp. - October 15, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc.(collectively the"Company"or"Marvel"), is pleased to announce that as a result of successful process development of the active pharmaceutical ingredient ("API") of its lead drug MB-204, the Company has now entered an important milestone of...

Marvel Biosciences Corp. to Present at the 22nd International Conference on Alzheimer’s Drug Discovery

Calgary, Alberta--(Newsfile Corp. - September 17, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc.(collectively the"Company"or"Marvel"), is pleased to announce that it has been accepted to present at the start-up company forum at the 22nd International Conference of Alzheimer's Drug Discovery, a virtual conference on October 4 and 5th, 2021...

Marvel Biosciences Corp. Updates Market on Its Lead Caffeine Inspired Asset MB-204 for Neurological Diseases

Calgary, Alberta--(Newsfile Corp. - August 5, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to provide an update on its lead compound asset MB-204 ("MB-204") being developed for neurological conditions such as depression and anxiety, Alzheimer's and ADHD. Marvel's compound is a novel...

Marvel Biosciences Corp. Retains Virtus Advisory Group To Provide Corporate Communications Services

2021-08-03 17:38 ET - News Release Mr. J. Roderick (Rod) Matheson reports MARVEL BIOSCIENCES CORP. RETAINS VIRTUS ADVISORY GROUP TO PROVIDE CORPORATE COMMUNICATIONS SERVICES Marvel Biosciences Corp. has retained Virtus Advisory Group Inc. to develop and implement a strategic corporate communications program to increase the company's exposure among industry stakeholders and investors across...

Marvel Biosciences Corp. To Commence CGMP Manufacturing Of Its Lead Asset MB-204

2021-07-21 12:37 ET - News Release Dr. Mark Williams reports MARVEL BIOSCIENCES CORP. TO COMMENCE CGMP MANUFACTURING OF ITS LEAD ASSET MB-204 Marvel Biosciences Corp.'s wholly owned subsidiary Marvel Biotechnology Inc. has achieved a significant science milestone in the development of its lead compound MB-204. Marvel Biotechnology has entered into a current good manufacturing process (cGMP)...

Alphanco receives conditional OK for Marvel acquisition

2021-03-18 16:43 ET - News Release Ms. Joanne Yan reports ALPHANCO VENTURE CORP. ANNOUNCES CONDITIONAL APPROVAL FOR ITS ACQUISITION OF MARVEL BIOTECHNOLOGY INC. Alphanco Venture Corp. has received conditional approval from the TSX Venture Exchange for its acquisition of all of the outstanding shares of Marvel Biotechnology Inc. as its proposed qualifying transaction as defined under TSX-V...